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display higher serum tryptase level, serum alkaline phosphatase level
and bone marrow mast cell burden (Table 1).
Next, we focused on SM-AHN-myeloid (n = 178), which included
11 (6%) patients with SM associated with acute myeloid leukemia
(SM-AML), 50 (28%) patients with SM associated with myeloprolifera-
tive neoplasms (SM-MPN), 24 (13%) patients with SM associated with
myelodysplastic syndromes (SM-MDS), 39 (22%) patients with SM
associated with chronic myelomonocytic leukemia (SM-CMML) and
54 (30%) patients with SM associated with MDS/MPN/unclassified
(SM-MDS/MPN/Unclassified). Figure 1C confirms the survival superi-
ority of SM-AHN-lymphoid, compared to any other specific category
of SM-AHN-myeloid. Prognostic comparison in SM-AHN-myeloid
(Figure 1C) is confounded by significant variation in age and risk distri-
bution of the specific myeloid components but appears to favor SM-
MPN and SM-MDS over other subcategories, including SM-CMML
and SM-MDS/MPN/Unclassified (Figure 1C).
We conclude that patients with SM-AHN-lymphoid are phenotypi-
cally and prognostically different than those with SM-AHN-myeloid and
should be cited as such in both clinical practice and future survival
studies in SM. Similarly, prognosis in SM-AHN-myeloid appears to
be dictated by the specific AHN component, which underscores
the need to be more specific in diagnostic assignment and treat-
ment directions. This is particularly important since sensitivity to
drug therapy or to other treatment modalities in SM might be dif-
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Management of diffuse large B-cell lymphoma (DLBCL) after failure of
front-line immunochemotherapy is a treatment challenge, without a
clear optimal salvage strategy, especially for patients not candidate to
autologous stem cell transplantation (ASCT).1 Few patients achieve
long-term disease control and no standard therapy exists. The British
Columbia Cancer Agency reported a median progression-free survival
(PFS) and overall survival (OS) of 2.1 and 3.9 months, respectively, in
326 patients who were not candidate for ASCT.2 Among most widely
used salvage regimens, the combination of rituximab and bendamus-
tine (BR) was associated with overall response (OR) ranging from
32 to 63%, and PFS of 3-8 months.3,4 When combined with cytara-
bine, bendamustine has demonstrated significant synergistic activity
in preclinical studies on DLBCL.5 Thus, we conducted a pilot trial to
explore the efficacy and tolerability of R-BAC (rituximab, bendamus-
tine, and cytarabine) in a cohort of patients with B cell relapsed/
refractory (R/R) aggressive lymphoma.
This study enrolled previously treated, histologically confirmed
DLBCL, either de-novo or transformed B-cell lymphoma (t-DLBCL),
treated with R-BAC between November 2012 and September 2017
in six Centers from Northern Italy. To be included patients had to be:
(1) treated with at least one previous line if not eligible for ASCT;
(2) treated with two or more previous lines of therapy including ASCT
or not; (3) aged 18 years or more, with no upper age limit; (4) not trea-
ted with prior bendamustine. The study was approved by the ethics
review board of the participating institutions and patients signed
informed consent before being enrolled. All histological diagnosis
were centrally reviewed by two expert hematopathologists (B.F. and
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E.SG.D.). The primary end-point was the complete remission (CR) rate.
Secondary end-points included OR, PFS, OS, duration of response
(DOR), and safety. The response rate was based on local radiologists
evaluation, and was evaluated according to Cheson criteria, 2007. A
boundary of 30% CR rate was considered indicative of a positive trial,
based on results obtained with BR in similar patient series.3,4 The R-
BAC regimen6 consisted of rituximab (375 mg/m2, Day 1 of the
cycle), bendamustine (70 mg/m2, Days 1-2, given as a 1-h infusion)
and cytarabine (500 mg/m2, Days 1-3, given as a 2-h infusion starting
2 h after bendamustine), administered every 21 days. Patients were
meant to receive at least four cycles, but in case of good tolerance
and/or partial response after four cycles patients continued treatment
to a maximum of six cycles. Patients older than 70 years or with poor
performance status (ECOG >2) not due to lymphoma progression had
cytarabine dose limited to Days 1 and 2. The same dose reduction
was applied to patients experiencing an excess of toxicity, defined as
hematological or non-hematological toxicity of Grade 4 lasting for
more than 5 days during any of the treatment cycle. Primary prophy-
laxis with granulocyte colony-stimulating factor was routinely used
starting from Day 5 after chemotherapy completion, and lasting for
3-6 days or until neutrophil count recovery.
Overall, 39 patients were included. Median age was 68 years
(range 21-84), and 23 (59%) were males. The majority of patients
(29, 74%) were recruited and treated in Vicenza, since other partici-
pating centers joined the study later in 2015. All patients had received
rituximab-CHOP (R-CHOP) or R-CHOP-like induction treatment,
median number of prior treatments was 2 (range 1-4), and six patients
(15%) had prior ASCT. The majority of patients (n = 21, 54%) had
refractory disease, with 23% of patients (n = 9) being double refrac-
tory (both to R-CHOP and R-DHAP). Median time from initial lym-
phoma diagnosis to enrollment was 21 months (range 4-120). Median
follow-up of the entire population from lymphoma diagnosis was
30 months (12-172). Patients characteristics are listed in Table 1.
Patients received a median of 4 cycles (range 1-6). Early discon-
tinuations (before cycle 4) were due to infections in 2 (1 had febrile
neutropenia in two consecutive cycles despite dose reductions, 1 had
colitis complicated by salmonellosis), and tumor progression in 10;
2 patients were consolidated with allogeneic stem-cell transplantation
after achieving CR; 4 patients were consolidated with ASCT;
20 patients (51%) had to delay or reduce treatment dose at least once
along cycles, however, delays lasted <14 days.
Overall, OR was 69% (CI 58-76), and CR was 41% (CI 32-48).
Among different histologies, OR was 78% in de novo DLBCL (CR 48%)
and 55% in t-DLBCL (CR 27%). Refractory patients had an OR of 48%
(CR 24%). The nine double refractory patients had an OR of 56% (2 CR,
3 PR, 2 stable disease, 2 progressive disease). Interestingly, tumor shrink-
age was observed in the majority of patients (79%), irrespective of tumor
histology (P = .23 by Mann-Whitney test), as shown in Figure 1A. Median
follow-up for survivors from study entry was 14 months (range 2-55).
Median PFS was 13.9 months, and median OS was 17.3 months
(Figure 1B,C). Median duration of response was 16 months, significantly
different between CR and PR (nr vs. 9.9 months, P = .05, Figure 1D). The
two patients receiving allogeneic transplant are still in remission after
52 and 25 months, respectively. Of the four patients that were consoli-
dated with ASCT, two experienced early relapse (2 and 5 months later)
and two are still in complete remission after 4 and 7 months, respec-
tively. At univariate analysis, the variables associated with a significantly
impaired PFS were refractory as opposed to relapsed disease (P = .03),
TABLE 1 Patients characteristics and treatment
Characteristics N = 39 (%)
Histology
De novo DLBCL 28/39 72
t-DLBCL 11/39 28
Age
Median (range) 68 (21-84)






Low (0-1) 9/39 23
Intermediate (2-3) 17/39 44





Median (range) 2 (1-4)
Prior therapies









Double refractoryb 9/39 23
Number of R-BAC cycles
Median (range) 4 (1-6)
≥4 cycles 19 49




Abbreviations: ASCT: autologous stem cell transplantation; CHOP: cyclo-
phosphamide, hydroxydaunorubicin, oncovin and prednisone; DHAP:
dexamethasone, cytarabine, cisplatin +/− rituximab; DLBCL: diffuse large
B cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group Perfor-
mance Status; GCB: germinal center B-cell like DLBCL; IPI: International
Prognostic Index; N: number; Non-GCB: nongerminal center DLBCL; PD:
progressive disease; t-DLBCL: transformed-DLBCL.
a Double refractory: R-CHOP and R-DHAP refractory.
b Cell of Origin was determined according to the Visco-Young algorithm.
c Two patients had infectious complications after the second cycle while
they were responding and were withdrawn from study treatment (see text
for details).
d Other: one patient refused to receive further therapy after he was in PR
after 3 cycles; two patients were consolidated with allogeneic stem-cell
transplant; four patients proceeded to autologous stem cell transplanta-
tion after 2-3 R-BAC cycles.
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shorter time since prior anti-lymphoma treatment (<6 vs. ≥6 months,
P = .007), and nongerminal center (GCB) cell-of-origin (non-GCB
vs. GCB, P = .01). Interestingly, international prognostic index (P = .15),
t-DLBCL as opposed to de novo DLBCL (P = .87), and number of prior
lines of therapy (1 vs. ≥2) were not associated with PFS (P = .57). Cox
proportional hazard model identified refractoriness to prior treatment as
the strongest independent prognostic variable in terms of PFS (P = .01,
hazard ratio, 3.88; 95% CI 1.37-11.71).
The primary toxicity was reversible myelosuppression. Grades
3-4 neutropenia (median duration 3 days, range 0-7) and thrombo-
cytopenia (median duration 4 days, range 0-8) occurred in 45% and
32% of patients, respectively. Febrile neutropenia occurred in two
patients (5%). There was no clear trend towards an increase in
cytopenia severity or transfusion requirements with subsequent
cycles. Most nonhematological adverse events attributed to R-BAC
were Grades 1-2, leaded by isolated gamma-glutamyl transferase
elevation (16%). Skin rash, sometimes accompanied by localized
itchy areas of cutaneous desquamation, was reported in 15%. No
secondary malignancy was observed during follow-up. Of the
15 deaths reported during the study, all patients except one were
attributed to disease progression. This patient died of unknown
cause while he was in remission. No toxic death has been reported.
No alopecia was observed.
In conclusion, R-BAC demonstrated promising anti-tumor activity in
this series of patients with de-novo or transformed aggressive lympho-
mas (2 median prior lines, and 54% refractory disease) unsuitable for
ASCT, with tumor shrinkage observed in 79% of patients. The response
rate compared favorably with previously reported prospective phase
two studies in R/R patients with DLBCL treated with the combination of
BR.3,4 Indeed, our patients presented with higher risk features compared
to patients enrolled in these trials, due to a worse performance status,
higher IPI and greater number of previous treatment lines.
Patients treated with R-BAC experienced mainly hematological
toxicity, as expected, which was managed with dose reductions.
Importantly, R-BAC was administered in outpatient setting in the
majority of patients. Based on our observations, R-BAC may warrant
further investigation in this setting, both as a bridge to allogeneic
stem-cell transplantation, or in combination with targeted therapies.
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FIGURE 1 A, Waterfall plot indicating maximum % of change from baseline sum of products of greatest diameters (SPD). Tumor shrinkage
was seen in 79% (31/39). Response was quantified by local radiologists of each participating center. B,C, Median PFS (Figure 1A) and OS
(Figure 1B) in 39 patients with relapsed-refractory aggressive B-cell lymphomas treated with R-BAC. D, Duration of response (nr vs.
9.9 months, P = .05)
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reduces buildup of potassium
and free hemoglobin in
washed red blood cells after
the procedure
To the Editor:
Stored red blood cells (RBCs) are washed in saline before transfusion
to remove residual plasma proteins and other contaminants present in
the storage medium. However, the levels of extracellular potassium
and free hemoglobin (Hb) in RBC units increase precipitously after
washing because of the cellular damage induced by centrifugation.
Here we tested whether our recently-developed centrifugation-free
washing system could reduce the accumulation of potassium and Hb
in the supernatant of washed RBCs during 24-h storage. Samples from
several RBC units (n = 7, storage duration 39-42 days) were washed
in normal saline either using the prototype of the centrifugation-free
washing system, or via centrifugation. The indicators of mechanical
damage (supernatant potassium, free Hb) and key metrics of RBC
in vitro quality (ATP, 2,3-DPG, deformability) were measured at 0, 3,
6 and 24 h after washing. RBC samples washed using the
centrifugation-free washing system had significantly lower concentra-
tion of free Hb (0.6  0.1 vs. 0.8  0.2 mg/mL) and potassium
(3.3  0.6 vs. 5.11  0.8 mmol/L) immediately after washing, and
their concentrations increased significantly less after the 24-hour stor-
age (Hb: 1.0  0.2 vs. 2.1  0.3 mg/mL; potassium: 4.9  0.6
vs. 10.5  0.9 mmol/L), than those washed by centrifugation. None
of the other measured parameters changed significantly during the
short-term storage. This study shows that our centrifugation-free
washing system could significantly reduce the buildup of potassium
and Hb in the supernatant of washed RBCs, potentially reducing the
risks that may be associated with their transfusion.
Stored red blood cells (RBCs) are washed before transfusion to
reduce the risk of complications associated with the residual plasma
proteins, excessive potassium, free hemoglobin (Hb) and other con-
taminants that may be present in the unit.1,2 Washing is typically per-
formed by diluting a standard 350 mL RBC unit with 1-2 L of normal
saline, and then concentrating the diluted RBCs back to the desired
hematocrit—with a centrifuge or a centrifugation-based cell
processor—and discarding the supernatant.2,3 Centrifugation, how-
ever, subjects stored RBCs to substantial mechanical damage, induc-
ing hemolysis and increasing fragility of the cells.3 As a result, the
levels of free Hb and potassium in RBC units increase progressively
after washing, reducing the clinical value of the procedure and sub-
jecting the recipients to a host of potential adverse outcomes.4 In this
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